Daratumumab, an anti-CD38 monoclonal antibody developed to target tumoral plasma cells in multiple myeloma (MM), induces the killing of CD38-bearing cells through different mechanisms of action (39). This evidence concerns the gene CD38 and AL amyloidosis.